Lawson Kroeker Investment Management Inc. NE Decreases Stock Position in AbbVie Inc. $ABBV

04 Apr 2026, 07:22 by Renee Jackson · The Cerbat Gem

Lawson Kroeker Investment Management Inc. NE lessened its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 62.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,768 shares of the company’s stock after selling 2,982 shares during the period. Lawson Kroeker Investment Management Inc. NE’s holdings in AbbVie were worth $404,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in ABBV. Chelsea Counsel Co. purchased a new stake in shares of AbbVie in the third quarter worth about $26,000. Westend Capital Management LLC purchased a new position in AbbVie during the 4th quarter valued at approximately $29,000. Texas Capital Bancshares Inc TX purchased a new position in AbbVie during the 3rd quarter valued at approximately $31,000. Evolution Wealth Management Inc. bought a new stake in AbbVie in the 2nd quarter worth approximately $26,000. Finally, Caitlin John LLC bought a new stake in AbbVie in the 3rd quarter worth approximately $33,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

AbbVie Price Performance

Shares of NYSE ABBV opened at $208.79 on Friday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The firm has a 50-day simple moving average of $221.58 and a two-hundred day simple moving average of $224.41. The company has a market cap of $369.17 billion, a P/E ratio of 88.47, a PEG ratio of 0.73 and a beta of 0.38.

AbbVie (NYSE:ABBV – Get Free Report) last released its earnings results on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The firm had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. During the same quarter in the prior year, the firm posted $2.16 earnings per share. The company’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities research analysts expect that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio is 293.22%.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on ABBV shares. Evercore lowered their target price on AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research report on Wednesday, February 4th. Morgan Stanley boosted their price target on shares of AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $223.00 price target on shares of AbbVie in a research note on Wednesday, January 28th. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $225.00 to $265.00 in a research note on Wednesday, December 10th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and an average price target of $253.15.

Read Our Latest Stock Report on AbbVie

Insiders Place Their Bets

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.25% of the company’s stock.

AbbVie Company Profile

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.